Merck & Co. reported earnings of $ 2.49 per MRK share on Oct 29, 2026, beating analysts' expectations by
| Report Date | Oct 29, 2026 |
|---|---|
| Forecasted EPS | $ 2.09 |
| Earnings Per Share (Surprise) | $ 2.49 (+$ 0.40) |
| Last Year's EPS | $ 2.24 |
| EPS YoY Change |
Out of the last 100 earnings reporting periods, Merck & Co. beat analysts’ expectations 78 times and fell short of expectations 9 time(s). Merck & Co. reported earnings per share of $ 2.49 in the last report surpassing an estimated EPS of $ 2.09 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Oct 29, 2026 | $ 2.09 | $ 2.49 | $ 2.58 | |
| Aug 4, 2026 | -$ 0.27 | -$ 0.13 | $ 2.13 | |
| Apr 30, 2026 | -$ 1.47 | -$ 1.28 | $ 2.22 | |
| Feb 3, 2026 | $ 2.01 | $ 2.04 | $ 1.72 | |
| Oct 30, 2025 | $ 2.36 | $ 2.58 | $ 1.57 | |
| Jul 29, 2025 | $ 2.03 | $ 2.13 | $ 2.28 | |
| Apr 24, 2025 | $ 2.13 | $ 2.22 | $ 2.07 | |
| Feb 4, 2025 | $ 1.85 | $ 1.72 | $ 0.03 | |
| Oct 31, 2024 | $ 1.50 | $ 1.57 | $ 2.13 | |
| Jul 30, 2024 | $ 2.15 | $ 2.28 | -$ 2.06 | |
| Apr 25, 2024 | $ 1.88 | $ 2.07 | $ 1.40 | |
| Feb 1, 2024 | -$ 0.09 | $ 0.03 | $ 1.62 | |
| Oct 26, 2023 | $ 1.95 | $ 2.13 | $ 1.85 | |
| Aug 1, 2023 | -$ 2.17 | -$ 2.06 | $ 1.87 | |
| Apr 27, 2023 | $ 1.32 | $ 1.40 | $ 2.14 | |
| Feb 2, 2023 | $ 1.56 | $ 1.62 | $ 1.80 | |
| Oct 27, 2022 | $ 1.67 | $ 1.85 | $ 1.75 | |
| Jul 28, 2022 | $ 1.70 | $ 1.87 | $ 1.31 | |
| Apr 28, 2022 | $ 1.83 | $ 2.14 | $ 1.40 | |
| Feb 3, 2022 | $ 1.53 | $ 1.80 | $ 1.32 |
Merck & Co.’s stock was trading at $ 140.93 on Oct 28, 2026 a day before the last earnings report was released.Following the release of the earnings report, MRK’s price increased to $ 149.52 on Oct 30, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Oct 29, 2026 | $ 2.49 | $ 140.93 | $ 149.52 | |
| Aug 4, 2026 | -$ 0.13 | $ 127.72 | $ 128.32 | |
| Apr 30, 2026 | -$ 1.28 | $ 110.95 | $ 112.16 | |
| Feb 3, 2026 | $ 2.04 | $ 113.37 | $ 118.33 | |
| Oct 30, 2025 | $ 2.58 | $ 86.58 | $ 85.98 | |
| Jul 29, 2025 | $ 2.13 | $ 84.06 | $ 81.75 | |
| Apr 24, 2025 | $ 2.22 | $ 78.69 | $ 82.74 | |
| Feb 4, 2025 | $ 1.72 | $ 99.79 | $ 89.67 | |
| Oct 31, 2024 | $ 1.57 | $ 104.83 | $ 101.88 | |
| Jul 30, 2024 | $ 2.28 | $ 127.78 | $ 113.13 | |
| Apr 25, 2024 | $ 2.07 | $ 127.00 | $ 131.20 | |
| Feb 1, 2024 | $ 0.03 | $ 120.78 | $ 126.41 | |
| Oct 26, 2023 | $ 2.13 | $ 103.63 | $ 102.82 | |
| Aug 1, 2023 | -$ 2.06 | $ 106.65 | $ 105.70 | |
| Apr 27, 2023 | $ 1.40 | $ 113.43 | $ 115.47 | |
| Feb 2, 2023 | $ 1.62 | $ 106.98 | $ 102.94 | |
| Oct 27, 2022 | $ 1.85 | $ 98.41 | $ 100.77 | |
| Jul 28, 2022 | $ 1.87 | $ 91.23 | $ 89.34 | |
| Apr 28, 2022 | $ 2.14 | $ 84.41 | $ 88.69 | |
| Feb 3, 2022 | $ 1.80 | $ 82.01 | $ 78.56 |
Merck & Co. released its most recent earnings reports in October 2026, August 2026, April 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Merck & Co. beat analysts’ expectations during the last earnings period by
